Cargando…

Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium

Numerous novel and effective therapeutic agents and clinical trials addressing castration-resistant prostate cancer (CRPC) were reported during the 2023 American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. Notably, radionuclide drug conjugates (RDC), specifically 177Lu/11...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Yuanhong, Wu, Siyu, Li, Rong, Yu, Jiazheng, Zheng, Jianyi, Li, Zeyu, Li, Mingyang, Xin, Kerong, Xu, Zhenqun, Li, Shijie, Chen, Xiaonan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391859/ https://www.ncbi.nlm.nih.gov/pubmed/37528464 http://dx.doi.org/10.1186/s40164-023-00430-1

Ejemplares similares

Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
por: Yu, Jiazheng, et al.
Publicado: (2023)

Scientific Advancements in Drug Development and Trials for Urothelial Carcinoma: Insights From the 2023 ASCO-GU Cancers Symposium
por: Feng, Dechao, et al.
Publicado: (2023)

Neues aus der Urologie von GU-ASCO, ASCO und EAU
por: Schnabel, Marco J., et al.
Publicado: (2020)

Hodentumoren: neue Erkenntnisse von ASCO-GU, ASCO und EAU 2021
por: Schrader, Mark
Publicado: (2021)

Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer
por: Li, Shijie, et al.
Publicado: (2023)

Highlights of ASCO 2023
por: Neugut, Alfred I, et al.
Publicado: (2023)

Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
por: Hou, Jiangxue, et al.
Publicado: (2023)

Genitourinary cancers updates: highlights from ASCO 2023
por: Qin, Qian, et al.
Publicado: (2023)

Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
por: Hou, Jiangxue, et al.
Publicado: (2023)

Abstracts from the 2023 SNO/ASCO CNS Cancer Conference
Publicado: (2023)

Associations between lumbar bone mineral density, serum 25-hydroxyvitamin D and history of kidney stones in adults aged 30–69 years in the USA (NHANES 2011–2018)
por: Li, Zeyu, et al.
Publicado: (2023)

CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
por: Liu, Xinyuan, et al.
Publicado: (2023)

BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
por: Wu, James F., et al.
Publicado: (2023)

Recent Advances in Gynecological Malignancies: Focus on ASCO 2023
por: Bodriagova, Olga, et al.
Publicado: (2023)

Nomograms for predicting overall and cancer-specific survival of patients with chromophobe renal cell carcinoma after nephrectomy: a retrospective SEER-based study
por: Zheng, Jianyi, et al.
Publicado: (2022)

Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application
por: Li, Mingyang, et al.
Publicado: (2023)

Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI)
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2018)

5-methylcytosine RNA methyltransferases and their potential roles in cancer
por: Li, Mingyang, et al.
Publicado: (2022)

Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
por: Zhao, Juanjuan, et al.
Publicado: (2023)

Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)
por: Choi, Yoon Ji, et al.
Publicado: (2018)

ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023
por: Cufer, Tanja, et al.
Publicado: (2023)

Knocking down NSUN5 inhibits the development of clear cell renal cell carcinoma by inhibiting the p53 pathway
por: Li, Lei, et al.
Publicado: (2023)

ASCO update: lung cancer
por: Absenger, Gudrun, et al.
Publicado: (2017)

New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
por: Roulleaux-Dugage, Matthieu, et al.
Publicado: (2023)

ASCO 2016: highlights in breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2016)

ASCO 2017: highlights in breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2017)

ASCO 2017—highlights of gynecological cancer
por: Radl, Bianca, et al.
Publicado: (2017)

ASCO 2020: highlights in breast cancer
por: Bartsch, Rupert
Publicado: (2021)

Current standards and practice changing studies in genitourinary (GU) cancers—a review of studies in localized/early GU cancers
por: Tan, W.C., et al.
Publicado: (2022)

Symposium Mammographicum 2023
Publicado: (2023)

ASCO 2018: highlights of urothelial cancer and prostate cancer
por: Pichler, Renate, et al.
Publicado: (2018)

Highlights in breast cancer from ASCO 2016
por: Cardoso, Fatima
Publicado: (2016)

ASCO highlights podcast: head and neck cancers
por: Merlano, Marco
Publicado: (2016)

ASCO 2018 highlights: metastatic breast cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2018)

ASCO: practice changing studies in gastrointestinal cancer
por: Prager, Gerald
Publicado: (2017)

Prognostic Characteristics and Immune Effects of N(6)-Methyladenosine and 5-Methylcytosine-Related Regulatory Factors in Clear Cell Renal Cell Carcinoma
por: Li, Lei, et al.
Publicado: (2022)

ASCO update on lymphoma
por: Fridrik, Michael A.
Publicado: (2017)

From ASCO 2022
por: Romero, Diana
Publicado: (2022)

Breast and gastrointestinal cancer updates from ASCO 2015
por: Dawood, Shaheenah
Publicado: (2015)

Proceedings of international symposium of trends in radiopharmaceuticals 2023 (ISTR-2023)
por: Jalilian, Amirreza, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j0lmgdgju9ubtkf0qo50lu9eng